Energy

Biogen CEO says $56,000 annually for Alzheimer’s drug is 'fair,' promises not to hike pric

Technology News || Energy News:


Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."
That being said, the Massachusetts-based biotech company has vowed to not increase the price of the drug, which is marketed under the name Aduhelm, for the next four years, Vounatsos said.

Biogen CEO Michel Vounatsos told CNBC on Monday that the list price of $56,000 per year for the company's FDA-approved Alzheimer's disease drug aducanumab is "fair."

That being said, the Massachusetts-based biotech company has vowed to not increase the price of the medication, which is marketed under the name Aduhelm, for the next four years, Vounatsos said.


The FDA's decision was highly anticipated. The drug is also expected to generate billions of dollars in revenue for the company and offers new hope to friends and families of patients living with the disease.

Biogen said Monday that aducanumab's list price is $56,000 per year, which was higher than the $10,000 to $25,000 price some analysts were expecting. The out-of-pocket cost for patients will depend on their health coverage.


Latest Breaking Technology News and Energy News Headlines & more

agribusiness marketplaces || Business || Health care industry || Politics || global politics || Occupy || Urban || spy satellites || Tesla Model || gig economy || GLOBAL ECONOMY || Biotech and Pharmaceuticals || Biotechnology || ag biotechnology || Breaking New || Latest Breaking Ne || Technology News



Source:  www.cnbc.com

Tags
Show More

Related Articles

Back to top button
Close